[go: up one dir, main page]

AU2002218744A1 - Bax fragment induced tumor cell death - Google Patents

Bax fragment induced tumor cell death

Info

Publication number
AU2002218744A1
AU2002218744A1 AU2002218744A AU1874402A AU2002218744A1 AU 2002218744 A1 AU2002218744 A1 AU 2002218744A1 AU 2002218744 A AU2002218744 A AU 2002218744A AU 1874402 A AU1874402 A AU 1874402A AU 2002218744 A1 AU2002218744 A1 AU 2002218744A1
Authority
AU
Australia
Prior art keywords
cell death
tumor cell
induced tumor
fragment induced
bax fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002218744A
Inventor
Ping Dou
Gui Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida St Petersburg
Original Assignee
University of South Florida
University of South Florida St Petersburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Florida, University of South Florida St Petersburg filed Critical University of South Florida
Publication of AU2002218744A1 publication Critical patent/AU2002218744A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2002218744A 2000-07-11 2001-07-11 Bax fragment induced tumor cell death Abandoned AU2002218744A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21726400P 2000-07-11 2000-07-11
US60/217264 2000-07-11
PCT/US2001/021971 WO2002003921A2 (en) 2000-07-11 2001-07-11 Bax fragment induced tumor cell death

Publications (1)

Publication Number Publication Date
AU2002218744A1 true AU2002218744A1 (en) 2002-01-21

Family

ID=22810317

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002218744A Abandoned AU2002218744A1 (en) 2000-07-11 2001-07-11 Bax fragment induced tumor cell death

Country Status (3)

Country Link
US (2) US20020022594A1 (en)
AU (1) AU2002218744A1 (en)
WO (1) WO2002003921A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106974A2 (en) * 2002-06-18 2003-12-24 Irm Llc Diagnosis and treatment of chemoresistant tumors
US20090162405A1 (en) * 2006-12-14 2009-06-25 Yong Qian Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells
WO2008104062A2 (en) * 2007-02-27 2008-09-04 University Of Manitoba Selective release of pro-apoptotic bcl-2 family members and their contribution to the bystander effect
WO2012122101A1 (en) * 2011-03-04 2012-09-13 Fox Chase Cancer Center Methods for inhibiting proliferation and inducing apoptosis of cancer cells expressing the g protein-coupled estrogen receptor gpr30
CN102226186B (en) * 2011-05-10 2013-01-23 深圳市赛百诺基因技术有限公司 Activated Bax gene for treating malignant tumor by taking adenovirus as carrier
CN114392345B (en) * 2021-03-11 2023-08-25 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） Use and method of E199L protein in promoting cell apoptosis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE22498T1 (en) * 1980-06-20 1986-10-15 Plessey Overseas METHOD AND EQUIPMENT FOR CHECKING COINS.
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4486104A (en) * 1981-12-28 1984-12-04 Smith International, Inc. Composite bearing
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) * 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5167616A (en) * 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5225182A (en) * 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
US5691179A (en) * 1993-08-26 1997-11-25 Washington University Cell death regulators
US6245885B1 (en) * 1998-10-05 2001-06-12 Mcgill University Bax-mediated apoptosis modulating reagents and methods

Also Published As

Publication number Publication date
US20030004111A1 (en) 2003-01-02
WO2002003921A2 (en) 2002-01-17
WO2002003921A3 (en) 2002-04-18
US20020022594A1 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
GB2397703C (en) Patch panel
AUPQ527400A0 (en) Gate latch
AU2001263341A1 (en) Snippet selection
AU2001296619A1 (en) Improved stopcock
IL142157A0 (en) An improved patch panel
AU2001253140A1 (en) Tumor markers in ovarian cancer
AU4125001A (en) Computer case
AU7030200A (en) Edgings
AU2000261840A1 (en) Bis-beta-hydroxyethyl terephthalate
AU2001290860A1 (en) Spas-1 cancer antigen
AU2001262202A1 (en) Fuel processor
AU2002218744A1 (en) Bax fragment induced tumor cell death
AU2002362613A1 (en) Galectins-1-and-4 in tumor development
AU2001282149A1 (en) Improved marker
AU5073201A (en) Ballistic protection
AU2002223788A1 (en) Tannages
AU2002316293A1 (en) Magnetic shield
AU2001290241A1 (en) Tumor cell proliferation inhibitors
AU2001288940A1 (en) Gene and sequence variation associated with cancer
AU2001250959A1 (en) Side panel latch
AU2001276979A1 (en) Magnetoresistive structure
AUPR036500A0 (en) Tumour radiotherapy
AUPR889601A0 (en) Improved dual fuel carburretor
AU2001290112A1 (en) Computer instructions
AU2001295812A1 (en) Register renaming